The Effects of Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-Gamma Agonist, on Markers of Endothelial Cell Activation, C-Reactive Protein, and Fibrinogen Levels in Non-Diabetic Coronary Artery Disease Patients

Journal of the American College of Cardiology

Volumn 42, Issue 10, 2003, Pages 1757-1763

  Sidhu, Jagdip S ^a   Cowan, Dahlia ^a   Kaski, Juan Carlos ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; PLACEBO; PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CELL ACTIVITY; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DATA ANALYSIS; DIET RESTRICTION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VERTIGO;

EID: 0242543997     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.04.001     Document Type: Article

References (45)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
2. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001;12:383-9.
3. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71.
4. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR-gamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR-gamma) expression and reduction of MMP-9 activity through PPAR-gamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17-23.
5. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998;95:7614-9.
6. Haffner SM, Miettinen H. Insulin resistance implications for type 2 diabetes and coronary heart disease. Am J Med 1997;103:152-62.
7. Sunayama S, Watanabe Y, Ohmura H, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999;146:187-93.
8. Kato K, Yamada D, Midorikawa S, et al. Improvement by the insulin-sensitising agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism 2000;49:662-5.
9. Arena R, Mitchell HE, Nylen ES, et al. Insulin action enhancement normalises brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 1998;28:1024-32.
10. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
11. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306-12.
12. Cominacini L, Garbin U, Fratta Pasini A, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998;47:130-3.
13. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
14. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk 2001;8:203-10.
15. Barnes PJ, Karin M. Nuclear factor-kappa-beta: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
16. Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999;48:1448-53.
17. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002;105:2296-302.
18. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000;101:235-8.
19. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR-alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-31.
20. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPAR-gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-52.
21. Chawla A, Boisvert WA, Lee CH, et al. A PPAR-gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161-71.
22. Chinetti G, Lestavel B, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7:53-8.
23. Moore KJ, Rosen ED, Fitzgerald ML, et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001;7:41-7.
24. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001;21:365-71.
25. Claudel T, Leibowitz MD, Fievet C, et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001;98:2610-5.
26. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000;106:523-31.
27. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001;21:372-7.
28. Friedwald WT, Levy RS, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
29. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
30. Blann AD, McCollum CN. Von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 1999;10:375-80.
31. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-90.
32. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-42.
33. Montalescot G, Collet JP, Choussat R, et al. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998;19 Suppl H:H11-7.
34. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
35. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
36. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
37. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804-9.
38. Wolfenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-7.
39. Phillips LS, Grunberger G, Miller E, et al. Once-and twice-daily dosing with rosiglitazone improves glycaemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15.
40. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001;7:162-9.
41. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11.
42. Rader DJ, Dugi KA. The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin Thromb Hemost 2000;26:521-8.
43. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 1998;18:723-31.
44. Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001;8:187-94.
45. Joukhadar C, Klein N, Schrolnberger C, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001;85:47-51.